Moreover, they speculated about how the CaSR could be a possible drug target using existing calcimimetics for the treatment of intestinal disorders, such as colorectal cancer and inflammatory bowel diseases (IBDs) (Iamartino et al., 2018). This evidence concerns the gene CASR and colorectal cancer.